Last reviewed · How we verify
NCT06335498: CS3
Further Study of AFGen1 Clinical Performance
trial testing ECG co-measurement in Atrial Fibrillation in 20 participants. Completed in 19 April 2024.
12 April 2024
Quick facts
| Lead sponsor | TriVirum, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 2 April 2024 |
| Primary completion | 12 April 2024 |
| Estimated completion | 19 April 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- ECG co-measurement
- Periodic ECG triggered measurement
Conditions studied
- Atrial Fibrillation — all drugs for Atrial Fibrillation →
- Afib — all drugs for Afib →
- ECG — all drugs for ECG →
Sponsor
TriVirum, Inc.
Who can join
Adults 18 to 90, any sex, with Atrial Fibrillation or Afib. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
AFGen1 is indicated for use on symptomatic or asymptomatic adults who are at risk of developing or who have atrial fibrillation, where a software assisted analysis of ambulatory ECG is needed to identify episodes of Afib. The purpose of this study is to establish further evidence for the clinical performance of AFGen1 on human participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06335498
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ECG co-measurement
Trials testing the same drug.
- NCT06076798 — Clinical Performance of AFGen1 · completed
Other recruiting trials for Atrial Fibrillation
Currently open trials in the same condition.
- NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
- NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
- NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
- NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
- NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting
Other TriVirum, Inc. trials
Trials by the same sponsor.
- NCT06076798 — Clinical Performance of AFGen1 · completed
- NCT05295056 — Clinical Performance of the AFGen1 Device Over a 7-day Period · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06335498 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by TriVirum, Inc.
- Last refreshed: 20 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06335498.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing